# PFE: Vyndamax Anchors 2029 Recovery

> Pfizer investor newsletter for May 6–10, 2026. Podcasts test how Vyndamax (tafamidis) supports the PFE bull case for a 2029 revenue recovery beyond the patent cliff.


## Pfizer: Vyndamax Supports 2029 Turnaround

**Week of May 6–10, 2026**

---

## Pfizer & Biopharma Weekly Newsletter

*Full podcast intelligence content pending import from source email. Run `scripts/fetch-podcast-emails.mjs` then `scripts/import-one.mjs` to populate this post with the complete analysis.*

---

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

---

```request-access
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```